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the knee at 3, 7, 14, 28, 56, 84, 112 days (n 8 per group). Changes in
subchondral bone at 28 days post DMM (n ¼ 6) were measured sepa-
rating the subchondral plate from the subchondral tabecular structures.
Results: Osteophytes were identiﬁed in 70% of mice by day 7 post DMM
and in all mice by day 14. At day 7 most samples had 1 or 2 osteophytes,
with somehavingup to 4 osteophytes by day 14. Fromday 28onwards the
osteophytes fused and formed into one or two large osteophytes. Osteo-
phytes increased in size and bone content with time, plateauing by day
112. The trabeculae of the subchondral bone at day 28 showed a sig-
niﬁcant (p<0.03) decrease in trabecular number on the medial side of
both theDMMand shamoperatedmicewhen compared to the respective
contralateral leg. In the sham samples, the reduction of trabecular num-
ber translated to a signiﬁcant increase in trabecular space, whereas in the
DMMmice an increase in trabecular thickness occurred, eliminating the
increase in trabecular space. Although bone changes occurred within a
week of DMM induction, cartilage damage scores were not signiﬁcant
until day 56 (p<0.05), compared to earlier time points.
Conclusions:We herein charachterised differential bone changes in the
DMM murine model of OA: there was accelerated osteophyte devel-
opment within the ﬁrst week, whereas subchondral bone changes were
not evident until day 28. Interestingly sham operated animals showed
subchondral trabecular bone loss in the ipsilateral knee, highlighting
the need to use the contralateral knee as an internal control. The early
bone changes in this OA model signiﬁcantly preceded cartilage degra-
dation, consistent with altered bone biology being an important driver
of OA pathogenesis.Supported By Arthritis Research UK (20199).
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Background: Osteoarthritis (OA) is a degenerative joint disorder,
characterized by the breakdown of articular cartilage, subchondral bone
thickening, osteophyte formation and synovial inﬂammation. The
human burden of this disease inﬂuences both the independence and
quality of life of those afﬂicted. Currently, there are no pharmaceutical
treatments to slow, stop or reverse disease progression, resulting in
greatly reduced quality of life for OA patients and the need for joint
replacement surgeries in many cases. The lack of available treatments
for OA is partially due to our incomplete understanding of themolecular
mechanisms promoting disease initiation and progression. Recent
ﬁndings from our laboratory indicate that activation of the transcription
factor PPARdelta induces the expression of enzymes involved in pro-
teoglycan breakdown and can lead to cartilage degeneration in OA,
prompting us to speculate whether inhibition of PPARdelta, can protect
from cartilage breakdown in OA.
Purpose:We aimed to characterize the role of PPARdelta in OA through
in-vitro, ex-vivo, and in-vivo studies to determine whether it is a fea-
sible target for OA therapy.
Hypothesis: We hypothesize that inhibition of PPARdelta will slow the
progression of OA in animal models.
Methods: Primary mouse chondrocytes and cartilage explants were
treated with a pharmacological PPARdelta agonist (GW501516) to
evaluate changes in gene expression (qPCR), and histology (Safranin-O,
immunohistochemistry) consistent with OA development. In order to
examine the role of PPARdelta in-vivo, cartilage-speciﬁc knockout mice
and wild-type littermate controls were subjected to destabilization of
medial meniscus surgery (DMM) at 20 weeks of age. 8 weeks post-
surgery mice were compared through classical histological and bio-
chemical measures of OA progression including Safranin-O staining
with OARSI scoring, immunohistochemistry for cartilage matrix
breakdown products, and picrosirius red staining for collagen ﬁber
structure and orientation.
Results: In vitro, PPARdelta agonism (by GW501516) results in the
upregulation of expression of proteases implicated in cartilage degen-
eration (including MMPs, and ADAMTS genes). Activation of PPARdelta
also results in proteoglycan breakdown in the cartilage matrix of an
explant culture system. Mice with cartilage-speciﬁc deletion of PPAR-
delta do not demonstrate any abnormalities in skeletal growth or
development, but do show signiﬁcant chondroprotection in comparisonto wild-type littermate controls after surgical induction of OA. OARSI
scoring and immunohistochemistry conﬁrm strong protection of
mutant mice against cartilage matrix breakdown, and decreased
breakdown products in the cartilage of PPARdelta knockout mice.
Conclusion: This study provides strong evidence for catabolic roles of
endogenous PPARdelta in post-traumatic OA and suggests that phar-
macological inhibition of PPARdelta is a promising therapeutic strategy.
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DKK3 PREVENTS MATRIX LOSS INDUCED BY PRO-INFLAMMATORY
CYTOKINES IN HUMAN CARTILAGE EXPLANTS
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Purpose: Osteoarthritis (OA) is a prevalent disease with high socio-
economic impact characterized by loss of articular cartilage. High-
lighted by a number of genetic and cell biology studies, the interception
of cell signaling pathways imply an important mechanism in OA
development and pathogenesis. Dkk3 is a member of the Dickkopf
family of WNT antagonists which is recently recognised to be upregu-
lated in OA cartilage. In the pathogenesis of OA the WNT signaling
pathway plays a role but the function of DKK3 in inﬂammation of joints
is still poorly described. According to recent reports the activation of
WNT signaling leads to an upregulation of TNF-a. In our study we
investigated the response of DKK3 in human OA cartilage explants to
the pro-inﬂammatory cytokines IL1-b and TNF-a.
Methods: Osteochondral explants (5mm) were created from human
femoral condyles (n ¼ 3 donors) of OA patients. The explants were
treated in duplicates with 10ng/ml IL1-b, 10ng/ml TNF-a and 10ng/ml
IL1-b þ 10ng/ml TNF-a for 21 days. Controls were left untreated. The
medium was collected for GAG analysis. Safranin-O stained parafﬁn
sections (2.5 mm) of the explants were assessed by Mankin score. The
release of glycosaminoglycans (GAG) from explants into the culture
medium was measured based on 1,9-dimethylmethylene blue binding.
For immunolabeling, explants were incubatedwithmonoclonal antibody
Dkk3 to determine whether an elevation in Dkk3 presence was asso-
ciated with the activation of TNF-a and IL1-b. Parafﬁn embedded 2.5mm
sections were deparafﬁnized and blocked with 10% donkey serum for 30
min, and incubated incubated overnight at 4C with antibodies against
Dkk3 in a dilution of 1:100 in 0.05 M Tris Buffer. After washing the slides
with TBS, the secondary antibody alexa ﬂuor 488 was applied for one
hour at room temperature containing 10mM 40,6-diamidino-2-phenyl-
indole (DAPI) for nuclear staining. The slides were observed under a
confocal laser scanning microscope connected to a digital imaging sys-
tem. Negative controls leaving the primary antibody were prepared. To
identify the ability of Dkk3 to reduce the activity of pro-inﬂammatory
cytokines on matrix loss, we incubated cartilages explants with 10ng/ml
recombinant human Dkk3 prior to IL1-b and TNF-a.
Results: Osteochondral explants show an increased loss of GAG and
differences in the Mankin score by the use of pro-inﬂammatory cyto-
kines IL1-b and TNF-a. Immunoﬂuorescence analysis using Dkk3 anti-
body showed that TNF-a/IL1-b treatment (10ng/ml, 21 days) promoted
an increased occurrence of Dkk3þ chondrocytes mainly in the surface
and superﬁcial zone of the cartilage fraction of the explants and lacking
positive staining in the deep zone compared to control. Treatment with
Dkk3 prior to IL1-b and TNF-a indicate a decreased GAG loss in explants.
Conclusions: The regulation of signaling in the pathogenesis of OA is
subjected to several parameters which inﬂuence also the balance and
activity of pro-inﬂammatory factors in joints. The appearance of Dkk3
protein is increased in OA and modiﬁed by IL1-b and TNF-a. Our data
shows the protective role of Dkk3 by its ability to decrease the loss of
matrix in the presence of IL1-b and TNF-a.
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Purpose: To evaluate the characteristics of the subchondral bone cysts
(SBCs) in osteoarthritis (OA) of the knee.
